Novo Nordisk (NYSE:NVO) said today that the FDA approved its Fiasp insulin aspart injection.
The fast-acting mealtime insulin is designed to improve glycemic control for adults with Type I and Type II diabetes. The injection can be taken at the start of a meal or within 20 minutes after starting a meal, Novo Nordisk reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Novo Nordisk wins FDA nod for fast-acting mealtime insulin appeared first on MassDevice.